Physician profile
Richard E Johnson
NPI 1568447969
$906.10
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $187.43 | 2019 | |
| Sun Pharmaceutical Industries INC. | $153.90 | 2019 | |
| Celgene Corporation | $119.60 | 2019 | |
| Prugen, INC. Pharmaceuticals | $113.69 | 2019 | |
| Amgen INC. | $63.93 | 2019 | |
| Novo Nordisk INC | $59.51 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $51.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $48.54 | 2019 | |
| Journey Medical Corporation | $42.00 | 2019 | |
| Lilly USA, LLC | $27.85 | 2019 | |
| Ucb, INC. | $15.43 | 2019 | |
| Pfizer INC. | $11.86 | 2019 | |
| Genzyme Corporation | $10.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.